Abstract: Disclosed herein are compounds that are Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Abstract: In some embodiments, a method for processing an optical fiber includes: drawing an optical fiber through a draw furnace, conveying the optical fiber through a flame reheating device downstream from the draw furnace, wherein the flame reheating device comprises one or more burners each comprising: a body having a top surface and an opposing bottom surface, an opening within the body extending from the top surface through the body to the bottom surface, wherein the optical fiber passes through the opening, and one or more gas outlets within the body; and igniting a flammable gas provided by the one or more gas outlets to form a flame encircling the optical fiber passing through the opening, wherein the flame heats the optical fiber by at least 100 degrees Celsius at a heating rate exceeding 10,000 degrees Celsius/second.

Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.

Abstract: The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: An aerosol delivery system has a nebulizer and a humidifier providing a gas flow to the nebulizer. A controller varies humidity level of the gas flow to the nebulizer so that if the nebulizer is not operating it has about 100% humidity and it is operating the value is less to allow for the humidification effect of the nebulizer. The control may be achieved by dynamically varying proportions of flow through a dry branch and a humidification branch.

Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.

Abstract: The present disclosure is directed to compounds that are inhibitors of HIF-2? having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Abstract: Oral formulations comprising a compound of Formula (I) and a chelating agent are provided, wherein compounds of Formula (I) have the structure: wherein, W, X, Y, Z, Ra, Rc, and each Rg are as defined herein. Also provided are methods of preparation, methods of use, and specific dosage forms.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: Compounds that inhibit PI3K?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3K?.

Abstract: A water main tapping device and method includes a saddle body including an arcuate portion between a first end and a second end, wherein the saddle body includes a saddle opening at a location between the first end and the second end, and a corporation stop body formed integrally with and extending from the saddle body. The corporation stop body includes a base with an inlet cavity in fluid communication with the saddle opening, a housing extending from the base and having a valve cavity in which a rotatable valve is positioned and which is in fluid communication with the inlet cavity, and a connector end extending from the housing and including an outlet in fluid communication with the valve cavity.

Abstract: An aerosol delivery system has a nebulizer and a humidifier providing a gas flow to the nebulizer. A controller varies humidity level of the gas flow to the nebulizer so that if the nebulizer is not operating it has about 100% humidity and it is operating the value is less to allow for the humidification effect of the nebulizer. The control may be achieved by dynamically varying proportions of flow through a dry branch and a humidification branch.

Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Abstract: A nebuliser control device has a manually adjustable user interface and a cable extending from the interface to a power source, and a cable extending from the interface to an aerosol generator. The interface is manually adjustable by physical movement of an actuator such a slider or a rotating knob to locally control the operation of the aerosol generator.

Abstract: The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

Abstract: A nebulizer device has an aerosol generator mounted in a housing, and a mouthpiece. The device is adapted for delivery of an active agent in an aerosol into the buccal cavity, with droplet size greater than 10 ?m. Aerosolization is started at or after the end of breath inhalation and is stopped at or before the start of breath inhalation. The flow is via mouthpiece with internal ridges which periodically narrow the flow path volume to so that droplets coalesce in the flow path before the mesh.